What you will learn
By the end of this topic, you should be able to define the biological-safety specialist’s role; establish the contact and material scope; plan a risk-based biological evaluation; integrate material characterisation, chemistry and toxicology; select testing only where needed; control suppliers and manufacturing effects; and assess changes and post-market signals.
The biological-safety specialist’s role
Biological safety is an application of risk management to the complete patient-contacting product. Specialists integrate contact, materials, processing, chemical information, toxicology, clinical use and existing evidence to determine whether biological risks are acceptable. Their role is not to select a standard test panel after the design is frozen.
Scope owner
Define patient-contacting components, exposure routes, duration and populations.
Evidence integrator
Combine material, chemical, toxicological, test and clinical evidence.
Risk adviser
Translate hazards and uncertainty into design and process decisions.
Change assessor
Evaluate supplier, material, process, packaging and use changes.
Define the real contact scenario
Identify every direct and indirect contact with the patient or user, including gas and fluid paths, degradation products, residues and substances transferred from packaging or processing. Characterise tissue type, route, frequency, duration, repeated use, cumulative exposure and affected population. Consider neonatal, pregnant, immunocompromised or otherwise vulnerable people where relevant.
Know what the finished device is made of
- Record material identity, grade, formulation, additives and colourants.
- Identify coatings, inks, adhesives, lubricants, cleaning agents and process aids.
- Understand supplier and sub-tier variability and change-notification controls.
- Consider joining, moulding, machining, washing, sterilisation and ageing effects.
- Assess interactions between components, drugs, specimens and use fluids.
- Trace evaluated materials to the manufactured and packaged configuration.
Use MTL-107 — Mechanical Design and Materials to connect material selection with wider design controls.
Create a biological-evaluation plan from risk and existing knowledge
Start with intended use, contact classification, material and process knowledge, prior data, clinical experience and relevant endpoints. Identify gaps and uncertainty, then select the least burdensome scientifically adequate method to address them. Document the rationale for evidence used, evidence not used and any testing omitted.
Use chemical characterisation to understand exposure
Plan extraction and analytical work around the actual device, materials, contact, sterilisation, ageing and use conditions. Define solvents, ratios, temperatures, durations, analytical evaluation thresholds and identification strategy. Treat unknowns and estimated quantities transparently. Chemical data need toxicological interpretation; a peak list alone is not a biological-safety conclusion.
Turn constituent data into a toxicological risk assessment
For each relevant constituent, assess hazard information, exposure, route, duration, susceptible populations and data quality. Document assumptions, uncertainty factors, tolerable exposure basis and mixture or local-effect considerations. Where evidence is insufficient, identify whether design change, supplier information, targeted analysis or testing is the appropriate response.
Test to resolve a defined gap
Select biological tests because they answer a remaining risk question, not because they appear in a generic matrix. Use representative finished, processed, sterilised and aged samples where those conditions affect exposure. Define extraction, controls, acceptance, deviations and interpretation in advance. Investigate unexpected or borderline results and connect conclusions back to the risk file.
Coordinate objective evidence with MTL-116 — Verification and Validation.
Control what manufacture can add or change
Translate safety-relevant material and process assumptions into specifications, approved suppliers, contamination controls, cleaning limits, sterilisation controls, packaging requirements and change notification. A safe prototype does not prove that routine production remains equivalent. Monitor residues, particulates, material variability and process excursions where they can affect exposure.
Maintain biological safety through change
Assess changes to formulation, source, site, tooling, process parameters, cleaning, sterilisation, packaging, shelf life, contact duration and clinical use before implementation. Use a documented comparison with the evaluated baseline. Complaints, sensitisation signals, irritation, unexpected reactions and new toxicological knowledge should trigger review.
Connect lifecycle assessment to MTL-129 — Configuration and Change Management.
Common misconceptions
“Medical grade means biocompatible.”
Supplier terminology does not establish safety for the finished device, process, contact and population.
“Passing tests proves biological safety.”
The conclusion depends on the complete evidence and risk assessment, not isolated pass results.
“The material did not change.”
Source, processing, residues, sterilisation, packaging and ageing can change patient exposure.
Authoritative starting points
Evaluate the finished device and its real exposure—not a material name
Biological safety depends on traceable knowledge of contact, composition, processing, exposure, toxicology and lifecycle change.